Skip to main content
ARS Home » Research » Publications at this Location » Publication #242464

Title: BACTERIOCIN E1073 PRODUCED BY ENTEROCOCCUS FAECIUM LWP1073 IS EFFECTIVE FOR TREATING COMMENSAL CLOSTRIDIUM PERFRINGENS INFECTION IN BROILERS

Author
item SVETOCH, E - State Research Center For Applied Microbiology And Biotechnology
item ERUSLANOV, B - State Research Center For Applied Microbiology And Biotechnology
item LEVCHUK, B - State Research Center For Applied Microbiology And Biotechnology
item PERELYGIN, V - State Research Center For Applied Microbiology And Biotechnology
item LUNEVA, N - State Research Center For Applied Microbiology And Biotechnology
item MITSEVICH, E - State Research Center For Applied Microbiology And Biotechnology
item BORZENKOV, B - State Research Center For Applied Microbiology And Biotechnology
item SVETOCH, O - State Research Center For Applied Microbiology And Biotechnology
item POKHILENKO, V - State Research Center For Applied Microbiology And Biotechnology
item STEPANSHIN, Y - State Research Center For Applied Microbiology And Biotechnology
item DYATLOV, I - State Research Center For Applied Microbiology And Biotechnology
item SIRAGUSA, G - Agtech
item Seal, Bruce
item Stern, Norman

Submitted to: Meeting Abstract
Publication Type: Abstract Only
Publication Acceptance Date: 7/28/2010
Publication Date: 10/19/2009
Citation: Svetoch, E.A., Eruslanov, B.V., Levchuk, B.P., Perelygin, V.V., Luneva, N.I., Mitsevich, E.V., Borzenkov, B.N., Svetoch, O.E., Pokhilenko, V.D., Stepanshin, Y.G., Dyatlov, I.A., Siragusa, G.R., Seal, B.S., Stern, N.J. 2009. BACTERIOCIN E1073 PRODUCED BY ENTEROCOCCUS FAECIUM LWP1073 IS EFFECTIVE FOR TREATING COMMENSAL CLOSTRIDIUM PERFRINGENS INFECTION IN BROILERS. Meeting Abstract.

Interpretive Summary:

Technical Abstract: Enterotoxin-producing Clostridium perfringens type A bacteria occupy a significant place in the etiological structure of food-borne infections in humans. One potential approach to minimize infections associated with food-borne pathogens is to control the carriage of C. perfringens in broilers. For this purpose we propose that a preparation of bacteriocin E1073 could be used (molecular mass of 3,256Da, pI = 8.2, 34 amino acids, class IIa, inhibits in vitro the growth of C. perfringens, Salmonella spp., Campylobacter spp.). For treating experimentally induced non-disease causing commensal C. perfringens-associated infection we used 14-day old commercial broilers. The infection was reproduced by challenging chickens with C. perfringens along with simultaneously providing them with a high roughage diet (50% rye flour + 50% fish meal). The birds were provided with drinking water added with bacteriocin E1073 in different concentrations for 3 days. The bacteriocin in doses of 32.8 and 16.9 mg/bird produced a significant therapeutic effect. The concentration of C. perfringens in control birds was 1.2 x 106 CFU per one gram of iliac homogenate versus C. perfringens-free samples from treated birds. Bacteriocin E1073 was also effective against mixed infections caused by C. perfringens and C. jejuni, and C. perfringens together with C. jejuni and S. enteritidis. These pathogens either were not identified or their concentrations were reduced by 103-106 CFU. Results demonstrated that bacteriocin E1073 is a promising therapeutic alternative to antibiotics for elimination of C. perfringens from pre-slaughter commercial broiler chickens.